



HAL
open science

The orexin story, sleep and sleep disturbances

Fabio Pizza, Lucie Barateau, Yves Dauvilliers, Giuseppe Plazzi

► **To cite this version:**

Fabio Pizza, Lucie Barateau, Yves Dauvilliers, Giuseppe Plazzi. The orexin story, sleep and sleep disturbances. *Journal of Sleep Research*, 2022, 31 (4), pp.e13665. 10.1111/jsr.13665 . hal-04493742

HAL Id: hal-04493742

<https://hal.science/hal-04493742>

Submitted on 7 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The orexin story, sleep and sleep disturbances

Fabio Pizza^{1,2} | Lucie Barateau^{3,4,5} | Yves Dauvilliers^{3,4,5}  | Giuseppe Plazzi^{2,6} 

¹Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

²IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

³Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France

⁴National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, and Kleine-Levin Syndrome, Montpellier, France

⁵Institute for Neurosciences of Montpellier, University of Montpellier, INSERM, Montpellier, France

⁶Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

Correspondence

Giuseppe Plazzi, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139 Bologna, Italy. Email: giuseppe.plazzi@isnb.it

Funding information

G Plazzi received funds for board engagements from Jazz, Bioprojet and Takeda. F Pizza received funds for travelling to conferences (Bioprojet), for speaking at symposia (Jazz), and for participating to advisory board (Takeda). Y Dauvilliers received funds for seminars, board engagements and travel to conferences by UCB Pharma, Jazz, Orexia, Idorsia, Takeda, Avadel and Bioprojet. L Barateau received funds for travelling to conferences by UCB Pharma and Bioprojet speaking honoraria from UCB Pharma, JAZZ and Bioprojet; board engagements from Jazz, Bioprojet and Takeda.

Summary

The orexins, also known as hypocretins, are two neuropeptides (orexin A and B or hypocretin 1 and 2) produced by a few thousand neurons located in the lateral hypothalamus that were independently discovered by two research groups in 1998. Those two peptides bind two receptors (orexin/hypocretin receptor 1 and receptor 2) that are widely distributed in the brain and involved in the central physiological regulation of sleep and wakefulness, orexin receptor 2 having the major role in the maintenance of arousal. They are also implicated in a multiplicity of other functions, such as reward seeking, energy balance, autonomic regulation and emotional behaviours. The destruction of orexin neurons is responsible for the sleep disorder narcolepsy with cataplexy (type 1) in humans, and a defect of orexin signalling also causes a narcoleptic phenotype in several animal species. Orexin discovery is unprecedented in the history of sleep research, and pharmacological manipulations of orexin may have multiple therapeutic applications. Several orexin receptor antagonists were recently developed as new drugs for insomnia, and orexin agonists may be the next-generation drugs for narcolepsy. Given the broad range of functions of the orexin system, these drugs might also be beneficial for treating various conditions other than sleep disorders in the near future.

KEYWORDS

insomnia, narcolepsy, orexin/hypocretin, sleep disturbances

1 | INTRODUCTION

Orexin (ORX)-A and ORX-B (or hypocretin; Hcrt-1 and -2) are neurotransmitters, cleaved from a single precursor peptide (prepro-ORX or prepro-Hcrt), which were discovered simultaneously by two research groups in 1998 (de Lecea et al., 1998; Sakurai et al., 1998). One group was searching for specific hypothalamic neurotransmitters, and named these peptides Hcrts given the specific expression in neurons located in the dorso-lateral hypothalamus together with amino-acid similarities

with the gut hormone secretin (de Lecea et al., 1998). Hcrt-producing neurons showed widespread projections within the hypothalamus, as well as to the thalamus and brainstem, and one peptide had an excitatory effect on cultured hypothalamic neurons (de Lecea et al., 1998). The other group disclosed that these neuropeptides stimulated food consumption and were upregulated during fasting, thus being a central feedback mechanism for the regulation of feeding behaviour (Sakurai et al., 1998). For their role in promoting feeding, the authors named the neurotransmitters ORXs (Sakurai et al., 1998).

ORX-A binds selectively to ORX-1 receptor (ORX1R), whereas both ORX-A and ORX-B bind to ORX-2 receptor (ORX2R), non-selectively. ORX1R and ORX2R are two G-protein-coupled receptors. ORXs are exclusively produced by a group of neurons localized in the lateral and dorsomedial hypothalamus (Peyron et al., 2000). In humans the number of Hcrt-producing neurons is estimated to be between 15–20 000 and 50–80 000 depending on the techniques used (in situ hybridization for prepro-ORX versus immunocytochemistry with anti ORX-A antibody; Fronczek et al., 2005; Peyron et al., 2000), and in the lateral hypothalamus they are intermingled with melanin-concentrating hormone-producing neurons (Aziz et al., 2008). Orexinergic projections are widespread throughout the central nervous system (Peyron et al., 1998), and thus are now known to be involved in a variety of functions and disorders (Jacobson et al., 2022). Across species, especially in mice and dogs, a disrupted ORX signalling leads to a narcoleptic phenotype with sleepiness, sleep instability and fragmentation, and cataplexy, unravelling a key role of ORXs in the regulation of sleep–wakefulness states (Saper et al., 2005). Despite ORX-A injection inducing feeding, it does not increase overall food consumption and body weight (Yamanaka et al., 1999), but conversely it plays a key role in reward mechanisms and motivational behaviour (Harris et al., 2005). Indeed, ORX-A secretion increases not only in relation to the wakefulness–sleep state, but maximally during positive emotion, social interaction and anger, thus modulating to complex human behaviours (Blouin et al., 2013; Sakurai, 2014). The ORX system is also involved in the hypothalamic regulation of several basic functions, such as autonomic control (Grimaldi et al., 2014), thermoregulation (Kuwaki, 2015) and energy homeostasis (Sakurai & Mieda, 2011), thus playing an important role in several human functions and disorders not limited to those affecting the central nervous system. In this review we will summarize the role of the ORX system in sleep and sleep disorders.

2 | SLEEP AND SLEEP DISTURBANCES

2.1 | ORX and normal sleep

The discovery of the ORX system led to a revolution on the conceptualization of sleep regulation. Indeed, the two-process model of sleep physiology included the integration of a homeostatic process (Process S) controlled by a circadian pacemaker (Process C) able to explain neurophysiological experimental data obtained in humans up to predict the time course of the sleep–wake rhythms and behavioural performances (Borbély et al., 2016). From the brain circuitry standpoint the regulation of sleep stands on the interaction between an ascending arousal system promoting wakefulness with different neuronal components located from the pons to the hypothalamus and thalamus and secreting several aminergic neurotransmitters and acetylcholine, and the opposite role of γ -aminobutyric acid (GABA)ergic modulation from the ventrolateral preoptic nucleus able to inhibit different targets (such as the locus coeruleus, dorsal raphe nucleus and tuberomammillary nucleus) of the arousal system. The discovery of orexinergic neurotransmission added a key point in sleep regulation as

long as ORXs conceptualized from basic experimental evidence as neurotransmitters able to promote wakefulness, but also to stabilize the “sleep” or “wake” state as long as the condition is established resulting in a “flip-flop” switch model (Saper et al., 2005). ORX neurons have strong projections to the wake–active brain areas, such as the locus coeruleus, dorsal raphe nucleus and tuberomammillary nucleus and others, and form the external stabilizer for this switch. Accordingly, the complete loss of ORX neurotransmission (as in narcolepsy type 1) results in state boundary dyscontrol (Broughton et al., 1986), with an inability to maintain wakefulness during daytime (Broughton et al., 1988) and to stabilize sleep during nighttime (Barateau et al., 2020; Maski et al., 2022), with the peculiar feature of increased sleep–wake transitions during nighttime in patients of all ages (Maski et al., 2020; Pizza et al., 2015). Moreover, sleep duration and continuity change across the life span, with frequent awakening during nocturnal sleep in the healthy elderly (Dijk et al., 2000) that is associated with a decline in sleep quality and quantity (Ohayon et al., 2004). Despite cerebrospinal fluid (CSF) levels of ORX not showing significant changes across ages (Kanbayashi et al., 2002a, 2002b), a reduction of the number of ORX neurons in the tuberal hypothalamic area was disclosed when comparing older subjects with infants and young adults (Hunt et al., 2015), thus indirectly suggesting that a decrease in ORX neurotransmission might play a role in sleep problems in the elderly. Recent experimental data showed that in aged mice ORX neurons are hyperexcitable and show more frequent activity leading to increased wake bouts, a finding possibly paving the way to therapeutic options (Li et al., 2022).

2.2 | ORX and sleep disturbances: Central disorders of hypersomnolence

After the discovery of the ORX system, its key role in the pathogenesis of primary sleep disorders was demonstrated, with narcolepsy being newly defined into narcolepsy type 1 (NT1, former narcolepsy with cataplexy) and narcolepsy type 2 (NT2, former narcolepsy without cataplexy) on the basis of having evidence of disrupted ORX system (American Academy of Sleep Medicine, 2014). The ORX system was therefore immediately a key pathophysiological and diagnostic element to dissect the spectrum of central disorders of hypersomnolence, and accordingly several studies reported the evidence obtained from CSF analyses in the different primary hypersomnolence disorders. As a result, we now look at central disorders of hypersomnolence dissecting them in orexinergic (i.e. NT1) and non-orexinergic (NT2, Kleine-Levin syndrome, idiopathic hypersomnia) ones, and a scientific debate is ongoing on how to better classify these disease entities (Fronczek et al., 2020; Lammers et al., 2020).

2.2.1 | NT1 and NT2

Narcolepsy is a rare sleep disorder, now split into two disease entities that are lumped by the neurophysiological evidence of rapid

occurrence of rapid eye movement (REM) sleep at sleep onset (SOREMP; Dement et al., 1966), a disease fingerprint well documented by the Multiple Sleep Latency Test (MSLT; Arand & Bonnet, 2019; Krahn et al., 2021).

Narcolepsy type 1 is clinically marked by a pentad of symptoms: excessive daytime sleepiness (EDS), sleep paralysis, hypnagogic/hypnopompic hallucinations, disturbed night sleep and cataplexy. Cataplexy is the pathognomonic symptom of NT1, and is characterized by a sudden occurrence of muscle weakness triggered by strong, most commonly positive, emotions (Kornum et al., 2017). While cataplexy phenotype is wide, with also subcontinuous weakness at disease onset in children possibly making its recognition challenging (Pillen et al., 2017), in NT2 it should be absent by definition (American Academy of Sleep Medicine, 2014). After the discovery of the ORXs, several scientific evidence discoveries connected their role to the pathophysiology of narcolepsy: first, a mutation in the gene coding for ORX2R was found as the cause of canine narcolepsy (Lin et al., 1999); second, in humans, ORX-producing neurons were found to be almost absent in the hypothalamus of deceased narcolepsy with cataplexy patients (Peyron et al., 2000; Thannickal et al., 2000). These data were associated with the possibility to document in vivo the deficiency of ORX-A in the CSF (defined as a level below 110 pg ml^{-1}) by means of a dedicated radioimmunoassay in narcolepsy with cataplexy (Nishino et al., 2000; Ripley et al., 2001), thus making this biological marker an exclusive diagnostic tool for narcolepsy with cataplexy. The evidence that ORX deficiency may forerun cataplexy occurrence (Andlauer et al., 2012) further contributed to the current definition of NT1 where cataplexy and ORX deficiency are considered equivalent (American Academy of Sleep Medicine, 2014). Conversely, ORX-A should be present in the CSF of NT2, together with the absent evidence of cataplexy (Bassetti et al., 2003; Dauvilliers et al., 2003; Heier et al., 2007), two key points that are shared by NT2 and the other central disorders of hypersomnolence (Baumann et al., 2014; Fronczek et al., 2020; Lammers et al., 2020). However, patients with NT2 may show a partly reduced number of ORX-producing neurons in the hypothalamus (Thannickal et al., 2009), despite CSF ORX levels comparable to those of healthy controls (Dauvilliers et al., 2003; Mignot et al., 2002). Recent data also showed that NT1 may be preceded by several years by EDS with SOREMPs before the occurrence of cataplexy (Pizza et al., 2014), and that CSF levels of ORX may decrease over time in a subset of narcolepsy patients with genetic predisposition (HLA DQB1*06:02) initially presenting with clinical features of NT2 (Lopez et al., 2017a; Pizza et al., 2014). Therefore, the exact role of ORX in determining NT2 is currently under debate, as well as the most appropriate cut-off (i.e. 110 versus 200 pg ml^{-1}) to identify ORX deficiency (Andlauer et al., 2012; Postiglione et al., 2022; van der Hoeven et al., 2022). At the same time, caution should be taken when diagnosing NT2 given the frequent occurrence of SOREMPs in patients with other sleep disorders (e.g. insufficient sleep syndrome, circadian rhythm sleep disorders) or under medications (Arand & Bonnet, 2019; Goldbart et al., 2014), thus making the role of careful clinical assessment and differential diagnosis crucial (Baumann et al., 2014).

While NT1 and NT2 are definite sleep-wake disorders occurring in otherwise healthy subjects, several neurological, genetic and paraneoplastic disorders may cause secondary narcolepsy (Kanbayashi et al., 2011; Nishino & Kanbayashi, 2005). Secondary narcolepsy may be related to inflammatory (e.g. multiple sclerosis) or tumoural lesions of the hypothalamus associated with EDS, and can have a favourable course along with resolution of the primary brain damage, as well as with antibody-mediated disorders such as neuromyelitis optica with anti-aquaporin-4 antibodies or limbic encephalitis of undetermined origin responsive to immunological approaches (Kanbayashi et al., 2011; Nishino & Kanbayashi, 2005). Otherwise, secondary narcolepsy can be paraneoplastic and tell-tale the presence of a tumour located outside of the central nervous system (Dauvilliers et al., 2013; Landolfi & Nadkarni, 2003; Overeem et al., 2004; Vitiello et al., 2018), with the link between the primary neoplasm (e.g. testicular, pulmonary) and the onset of narcolepsy being the presence of specific antibodies such as anti-Ma2 or anti-Hu (Dauvilliers et al., 2013; Landolfi & Nadkarni, 2003; Overeem et al., 2004; Vitiello et al., 2018) or unknown (Rossi et al., 2021). In most of these paraneoplastic cases narcolepsy occurs in patients not carrying the genetic predisposition (HLA-DQB1*06:02), may have variable levels of CSF ORX-A up to clear deficiency, and the evolution of the disease is frequently variable and linked to that of the primary disorder. Other causes of secondary narcolepsy may be genetically determined disorders occurring at different ages of life. In young children, and more rarely adults, Niemann Pick type C disease should be clinically suspected when sleepiness or cataplexy are associated with hepatosplenomegaly, vertical supranuclear saccadic palsy, ataxia, dystonia and dementia (Imanishi et al., 2020; Kandt et al., 1982). The evidence of cataplexy, as well as of mildly reduced CSF levels of ORX-A, in patients with other neurological signs and symptoms may therefore lead to prompt diagnosis of the autosomal recessive storage disorder, thus paving the way to treatment able to modify disease evolution (including the progression of ORX deficiency; Imanishi et al., 2020). Finally, there are autosomal-dominant familial pedigrees where narcolepsy with cataplexy progressively occurs (about 30–40 years of age) within a widespread neurological involvement including cerebellar ataxia and deafness (Autosomal-Dominant Cerebellar Ataxia, Deafness and Narcolepsy; ADCA-DN) leading to premature death (Melberg et al., 1995), a neurodegenerative condition that includes evidence of ORX-A deficiency in the CSF (Melberg et al., 2001). Mutations in DNMT1 gene encoding for a DNA methyltransferase involved in the epigenetic modulation of gene expression in different tissues have been recently linked to ADCA-DN (Winkelmann et al., 2012), as well as with another autosomal-dominant disorder characterized by peripheral neuropathy, hearing loss, premature dementia and in some cases narcolepsy without cataplexy (Hereditary Sensory and Autonomic Neuropathy with Dementia and Hearing loss type IE; HSNAN IE; Moghadam et al., 2014). While optic atrophy and daytime sleepiness with SOREMPs may lump these two neurodegenerative conditions, cataplexy is typical of ADCA-DN and associated with evidence of reduced levels of ORX-A in the CSF confirming the role of the orexinergic system in the pathophysiology of cataplexy across different diseases (Moghadam

et al., 2014). Unfortunately, even if pathophysiological research is ongoing on disease mechanisms leading to neurodegeneration in DNMT1-related disorders (Maresca et al., 2020), no curative approach is available to date. As a whole, secondary narcolepsy should be suspected when the disease occurs in familial cluster, in association with other neurological symptoms/signs, and in the absence of typical biological fingerprints (genetic predisposition, intermediate CSF levels of ORX-A).

2.2.2 | Idiopathic hypersomnia

Idiopathic hypersomnia is a central hypersomnolence disorder characterized by EDS, long non-refreshing naps, sleep inertia at awakening (Roth, 1981) and prolonged nocturnal sleep, as well elevated time spent asleep across the 24 hr (Evangelista et al., 2018; Vernet & Arnulf, 2009). Idiopathic hypersomnia is formally differentiated from narcolepsy for the occurrence of SOREMPs at the MSLT (Arand & Bonnet, 2019; Krahn et al., 2021), an unstable neurophysiological fingerprint given the low test–retest reliability of the test itself in non-cataplectic hypersomnolence disorders (Lopez et al., 2017b; Ruoff et al., 2018; Trotti et al., 2013). Accordingly, the diagnostic criteria have changed over time leading to heterogeneous case series published in the literature, and currently a prolonged (conventionally established above 11 hr) 24-hr sleep time is accepted as objective neurophysiological confirmation (American Academy of Sleep Medicine, 2014), despite different protocols used worldwide to quantify sleep needs across the 24 hr (Fronczek et al., 2020; Lammers et al., 2020). Few data addressed CSF levels of ORX-A in idiopathic hypersomnia, and there is no evidence to date pointing to a reduction of the neurotransmitter in these patients compared with otherwise healthy, or subjectively sleepy, controls (Dauvilliers et al., 2003; Kanbayashi et al., 2002a, 2002b; Mignot et al., 2002; Pizza et al., 2015). Therefore, if any, the role of the orexinergic system in idiopathic hypersomnia seems limited, and warrants further research.

2.2.3 | Kleine-Levin syndrome

Kleine-Levin syndrome is a peculiar central disorder of hypersomnolence characterized by recurrent episodes of hypersomnolence with long sleep duration for days associated with behavioural, cognitive, perceptual and eating disturbances, and separated by periods with normal alertness, cognition, mood and behaviour (American Academy of Sleep Medicine, 2014). The disorder generally arises in adolescence, and most frequently resolves spontaneously over time with acute attacks becoming progressively shorter as well as less intense, and intermixed by normal alertness for more prolonged periods up to spontaneous resolution (Arnulf et al., 2012; Lavault et al., 2015). CSF ORX-A levels were reported within the normal range in between hypersomnia episodes, but when retested in the same patients during the episodes a significant decrease was reported in several case series (Dauvilliers et al., 2003; Lopez et al., 2015; Podestá

et al., 2006; Usuda et al., 2018; Wang et al., 2016). CSF ORX-A level fluctuations appeared within values considered above the diagnostic cut-off for NT1 in most patients (Podestá et al., 2006; Usuda et al., 2018), but in some cases also a reduction up to below 110 pg ml⁻¹ was reported (Lopez et al., 2015; Wang et al., 2016). It is therefore unclear the relation between hypersomnia episodes and CSF ORX levels, whereas a recent study disclosed that polymorphisms of the TRANK1 gene (already associated with bipolar disorder and schizophrenia) constitute a genetic predisposition to the disorder (Ambati et al., 2021).

2.2.4 | ORX-based therapies

Current treatments of narcolepsy are symptomatic, but often not sufficient and even with treatment patients have reduced quality of life. In this context and because of the specific pathophysiology of NT1, ORX-based therapies are the most promising treatment for NT1, and possibly also for other patients with EDS. Accordingly, since the discovery of ORX deficiency in narcolepsy, several approaches have been considered: intranasal administration of ORX peptides, development of ORX-receptor agonists, ORX neuronal transplantation, transforming stem cells into ORX neurons and ORX gene therapy (Table 1). The activation of ORX2R was particularly expected to promote wakefulness, as narcolepsy-like phenotypes (with wakefulness fragmentation) are observed in ORX2R knockout mice, but not in ORX1R knockout mice.

Orexin replacement therapy has remained complicated so far, as both peptides poorly cross the blood–brain barrier (Fujiki et al., 2003). ORX administration (per os and intravenous) in animal models of NT1 was almost unsuccessful because of this impermeability. Nevertheless, the direct administration of ORX intraventricularly suppressed narcoleptic symptoms in a mouse model (ORX/ataxin-3 neuron-ablated; Mieda et al., 2004). Furthermore, slow infusion of ORX delivered via a chronically implanted intrathecal catheter in another mouse model (ORX knockout mice) decreased cataplexy and SOREMPs (Kaushik et al., 2018). A few preclinical and clinical studies showed the promising effect of a non-invasive method via intranasal administration of ORX, targeting drugs almost “directly” to the brain along the olfactory and trigeminal neural pathways (Deadwyler et al., 2007; Weinhold et al., 2014). Non-peptide ORXR agonists, currently under development, are very promising to treat narcolepsy. A first study showed that systemic administration of a selective ORX2R agonist improved symptoms in mice models of narcolepsy, with the suppression of cataplexy and the promotion of wakefulness, providing a proof of concept for a mechanistic therapy of NT1 by ORX2R agonists (Irukayama-Tomobe et al., 2017). However, this compound had a limited in vivo efficacy, and was finally not suitable for clinical development. Then another ORX2R-selective agonist (TAK-925) showed a major wake-promoting effect in wild-type mice and non-human primates when injected intravenously, and increased wakefulness and suppressed cataplexy in ORX/ataxin-3 transgenic mice (Suzuki et al., 2018; Yukitake et al., 2019). It also attenuated the body weight gain, without

TABLE 1 Overview of ORX/Hcrt-based therapies tested (and published) in animal models of narcolepsy and in human narcolepsy (adapted from Barateau & Dauvilliers, 2019)

ORX-based therapy	Administration, methods	Animal/human subjects	Impact on symptoms	References
ORX-A replacement	IV (very high doses) and intrathecal ORX-A	ORX-ligand- deficient narcoleptic dog	IV administration: transient reduction of cataplexy, no effect on sleep; intrathecal: no effect	Fujiki et al. (2003)
	Intracerebroventricular ORX-A	ORX-neuron-ablated mice	Reduction of cataplexy and sleepiness	Mieda et al. (2004)
	Intranasal ORX-A	Sleep-deprived rhesus monkeys	Reduction of the effects of sleep deprivation on cognitive performances	Deadwyler et al. (2007)
	Intranasal ORX-A	n = 8 patients with NT1	No effect on cataplexy Reduction of REM sleep quantity, stabilization of REM sleep (reduced direct wake-to-REM transitions)	Baier et al. (2011)
	Intranasal ORX-A	n = 14 patients with NT1	No effect on cataplexy Reduction of REM sleep duration, stabilization of REM sleep (less wake-REM sleep transitions)	Weinhold et al. (2014)
Non-peptide selective ORX2R agonist	Intracerebroventricular and intraperitoneal (YNT- 185)	Models of narcoleptic mice	Reduction of sleepiness and cataplexy (also promotes wakefulness in wild-type mice, IV administered)	Irukayama-Tomobe et al. (2017)
	Subcutaneous administration of TAK-925 (full agonist)	Wild-type mice, models of narcoleptic mice	Promotion of wakefulness in wild-type mice, but not in ORX2R-KO mice	Yukitake et al. (2019)
ORX cell transplantation	Implantation of ORX neurons in the lateral hypothalamus	Neurotoxin-ablated ORX neuron rats	Reduction of sleepiness	Arias-Carrión and Murillo-Rodríguez (2014)
ORX gene therapy	Overexpression of prepro-ORX transgene	Models of narcoleptic mice	Reduction of cataplexy, stabilization of REM sleep, slight effect on sleepiness	Blanco-Centurion et al. (2013); Kantor et al. (2013)
	Transient expression of ligand in the lateral hypothalamus with herpes simplex vector	ORX-KO mice	Reduction of cataplexy, increased REM sleep	Liu et al. (2008)
	Delivery of the ORX gene into brain areas using recombinant adeno-associated viral vectors	Models of narcoleptic mice	Reduction of cataplexy	Liu et al. (2011, 2016)

Notes: IV, intravenous; KO, knockout; NT1, narcolepsy type 1; ORX, orexin/hypocretin; REM, rapid eye movement.

changing the daily food intake (Kimura et al., 2019). Of interest, the persistence of the effect after a 14-day period of chronic administration suggested an absence of ORX2R desensitization. Other new promising non-peptide ORXR agonists (TAK-994 and TAK-861) with per os administration are also currently under development (Ishikawa et al., 2019; Ishikawa et al., 2020). The development of ORX2R agonists could also be of interest in patients with sleepiness and normal CSF ORX-A levels: NT2, idiopathic hypersomnia or even hypersomnolence in other conditions such as sleep apnea (ClinicalTrials.gov identifiers: NCT04091425, NCT04091438). Other ORX-based therapies were tested with success in rodents, such as cell replacement technique using ORX neurons derived from pluripotent stem cells (Arias-Carrión & Murillo-Rodríguez, 2014), and could eventually be an option for very severe or pharmaco-resistant patients

(Barateau & Dauvilliers, 2019). At last, ORX gene therapy improved symptoms in narcoleptic mice, but those findings remain preliminary (Blanco-Centurion et al., 2013; Kantor et al., 2013; Liu et al., 2008; Liu et al., 2011, 2016).

3 | INSOMNIA AND ORXR ANTAGONISTS

The discovery of the Hcrt system opened a new era of development of new drugs in the field of sleep medicine. Indeed, besides the research of ORXR agonists and in general orexinergic agents for the treatment of NT1, and hopefully for its natural borderland, impressive research focused on the development of Hcrt-R1/Hcrt-R2 antagonists (Brisbare-Roch et al., 2007). These drugs aim at competitively binding

ORXRs to blunt the orexinergic-mediated maintenance of wakefulness. To date, five drugs targeting both orexinergic receptors (namely dual ORX receptor antagonists; DORAs) have been used in clinical trials: suvorexant (Herring et al., 2012; Herring et al., 2016; Herring et al., 2020; Michelson et al., 2014); almorexant (Black et al., 2017; Hoever et al., 2012; Roth et al., 2017), filorexant (Connor et al., 2016); lemborexant (Kärppä et al., 2020; Murphy et al., 2017; Rosenberg et al., 2019); and daridorexant (Dauvilliers et al., 2020; Mignot et al., 2022; Zammit et al., 2020). These drugs proved efficacious against placebo on several objective sleep parameters, including sleep efficiency, total sleep time and wakefulness after sleep onset (Xue et al., 2022). Almorexant reached clinical trials phase 3, but was later discontinued due to liver enzyme increase, while suvorexant and lemborexant have been approved by FDA for the treatment of insomnia in 2014 and 2019, respectively, and daridorexant completed the phase 3 trials obtaining the FDA approval and is currently under evaluation by EMA. DORAs did not show main side-effects on memory and cognition, and the most commonly reported side-effects are somnolence, abnormal dreams, fatigue and dry mouth (Xue et al., 2022).

More recently, selective ORX receptor-2 antagonists (2-SORAs) have been developed and applied in clinical samples (Brooks et al., 2019; De Boer et al., 2018), opening new avenues in our comprehension of the role of ORX signalling manipulation (and role) in patients with insomnia (Clark et al., 2020). Indeed, when comparing the effect of DORAs and 2-SORAs on sleep architecture, both approaches increased total sleep time, but acted differently on sleep architecture in healthy subjects and in patients with insomnia. DORAs increased total sleep time mostly by increasing REM sleep, an effect more evident in patients with insomnia compared with healthy subjects given the potential near-ceiling levels of total sleep time and REM sleep time in healthy sleepers (Clark et al., 2020). Conversely, 2-SORAs increased total sleep time by means of increasing both non-REM and REM sleep, a finding that needs further research also in experimental models and healthy sleepers (Gotter et al., 2016). This evidence paves the way to better phenotyping insomnia patients, also taking into account psychiatric comorbidity, and to obtain key information on the role of the orexinergic system dysfunction in the determination of insomnia itself.

4 | CONCLUSIONS

The ORX system discovery is new in the field of sleep medicine. Its role is crucial in the regulation of sleep and wakefulness, as well as in modulating several behaviours and function in humans. While a complete defect of the ORX system is causal of narcolepsy, other central disorders of hypersomnolence may be influenced directly (lesion) or indirectly (immune-mediated) by processes affecting altering orexinergic neurotransmission. Accordingly, new drugs replacing ORX function are highly promising for the treatment of central disorders of hypersomnolence. On the other side, recent evidence in patients with insomnia showed different impacts in sleep architecture of drugs blocking ORX2R or ORX2R/ORX1R, possibly leading to a

better comprehension of the orexinergic role in sleep maintenance. Overall, the manipulation of the orexinergic system will unravel complex relations between sleep and sleep disorders in healthy subjects, in patients with sleep disorders and other conditions affecting the central nervous system from a neurological and psychiatric standpoint.

CONFLICT OF INTEREST

The authors declare no conflicts of interest related to this article.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available in [repository name] at [URL/DOI], reference number [reference number]. These data were derived from the following resources available in the public domain: [list resources and URLs]

ORCID

Yves Dauvilliers  <https://orcid.org/0000-0003-0683-6506>

Giuseppe Plazzi  <https://orcid.org/0000-0002-1051-0472>

REFERENCES

- Ambati, A., Hillary, R., Leu-Semenescu, S., Ollila, H. M., Lin, L., During, E. H., Farber, N., Rico, T. J., Faraco, J., Leary, E., Goldstein-Piekarski, A. N., Huang, Y. S., Han, F., Sivan, Y., Lecendreux, M., Dodet, P., Honda, M., Gadoth, N., Nevsimalova, S., ... Mignot, E. J. (2021). Kleine-Levin syndrome is associated with birth difficulties and genetic variants in the TRANK1 gene loci. *Proceedings of the National Academy of Sciences of the United States of America*, 118, e2005753118. <https://doi.org/10.1073/pnas.2005753118>
- American Academy of Sleep Medicine. (2014). *International classification of sleep disorders - Third edition (ICSD-3)*. American Academy of Sleep Medicine.
- Andlauer, O., Moore, H., 4th, Hong, S. C., Dauvilliers, Y., Kanbayashi, T., Nishino, S., Han, F., Silber, M. H., Rico, T., Einen, M., Kornum, B. R., Jennum, P., Knudsen, S., Nevsimalova, S., Poli, F., Plazzi, G., & Mignot, E. (2012). Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. *Sleep*, 35, 1247–55F. <https://doi.org/10.5665/sleep.2080>
- Arand, D. L., & Bonnet, M. H. (2019). The multiple sleep latency test. *Handbook of Clinical Neurology*, 160, 393–403. <https://doi.org/10.1016/B978-0-444-64,032-1.00026-6>
- Arias-Carrión, O., & Murillo-Rodríguez, E. (2014). Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats. *PLoS One*, 9, e95342. <https://doi.org/10.1371/journal.pone.0095342>
- Arnulf, I., Rico, T. J., & Mignot, E. (2012). Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. *The Lancet. Neurology*, 11, 918–928. [https://doi.org/10.1016/S1474-4422\(12\)70187-4](https://doi.org/10.1016/S1474-4422(12)70187-4)
- Aziz, A., Fronczek, R., Maat-Schieman, M., Unmehopa, U., Roelandse, F., Overeem, S., van Duinen, S., Lammers, G. J., Swaab, D., & Roos, R. (2008). Hypocretin and melanin-concentrating hormone in patients with Huntington disease. *Brain Pathology*, 18, 474–483. <https://doi.org/10.1111/j.1750-3639.2008.00135.x> Epub 2008 May 22.
- Baier, P. C., Hallschmid, M., Seeck-Hirschner, M., Weinhold, S. L., Burkert, S., Diessner, N., Göder, R., Aldenhoff, J. B., & Hinze-Selch, D. (2011). Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. *Sleep Medicine*, 12, 941–946. <https://doi.org/10.1016/j.sleep.2011.06.015>
- Barateau, L., & Dauvilliers, Y. (2019). Recent advances in treatment for narcolepsy. *Therapeutic Advances in Neurological Disorders*, 12, 1756286419875622. <https://doi.org/10.1177/1756286419875622>

- Barateau, L., Lopez, R., Chenini, S., Rassin, A. L., Scholz, S., Lotierzo, M., Cristol, J. P., Jaussent, I., & Dauvilliers, Y. (2020). Association of CSF orexin—A levels and nocturnal sleep stability in patients with hypersomnolence. *Neurology*, *95*, e2900–e2911. <https://doi.org/10.1212/WNL.00000000000010743> Epub 2020 Sep 1.
- Bassetti, C., Gugger, M., Bischof, M., Mathis, J., Sturzenegger, C., Werth, E., Radanov, B., Ripley, B., Nishino, S., & Mignot, E. (2003). The narcoleptic borderland: A multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin a). *Sleep Medicine*, *4*, 7–12. [https://doi.org/10.1016/s1389-9457\(02\)00191-0](https://doi.org/10.1016/s1389-9457(02)00191-0)
- Baumann, C. R., Mignot, E., Lammers, G. J., Overeem, S., Arnulf, I., Rye, D., Dauvilliers, Y., Honda, M., Owens, J. A., Plazzi, G., & Scammell, T. E. (2014). Challenges in diagnosing narcolepsy without cataplexy: A consensus statement. *Sleep*, *37*, 1035–1042. <https://doi.org/10.5665/sleep.3756>
- Black, J., Pillar, G., Hedner, J., Polo, O., Berkani, O., Mangialaio, S., Hmissi, A., Zammit, G., & Hajak, G. (2017). Efficacy and safety of almorexant in adult chronic insomnia: A randomized placebo-controlled trial with an active reference. *Sleep Medicine*, *36*, 86–94. <https://doi.org/10.1016/j.sleep.2017.05.009> Epub 2017 May 29.
- Blanco-Centurion, C., Liu, M., Konadhode, R., Pelluru, D., & Shiromani, P. J. (2013). Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice. *Sleep*, *36*, 31–40. <https://doi.org/10.5665/sleep.2296>
- Blouin, A. M., Fried, I., Wilson, C. L., Staba, R. J., Behnke, E. J., Lam, H. A., Maidment, N. T., Karlsson, K. Å., Lapiere, J. L., & Siegel, J. M. (2013). Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. *Nature Communications*, *4*, 1547. <https://doi.org/10.1038/ncomms2461>
- Borbély, A. A., Daan, S., Wirz-Justice, A., & Deboer, T. (2016). The two-process model of sleep regulation: A reappraisal. *Journal of Sleep Research*, *25*, 131–143. <https://doi.org/10.1111/jsr.12371> Epub 2016 Jan 14.
- Brisbare-Roch, C., Dingemans, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., Mueller, C., Naylor, O., van Gerven, J., de Haas, S. L., Hess, P., Qiu, C., Buchmann, S., Scherz, M., Weller, T., Fischli, W., Clozel, M., & Jenck, F. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. *Nature Medicine*, *13*, 150–155. <https://doi.org/10.1038/nm1544> Epub 2007 Jan 28.
- Brooks, S., Jacobs, G. E., de Boer, P., Kent, J. M., Van Nueten, L., van Amerongen, G., Zuiker, R., Kezic, I., Luthringer, R., van der Ark, P., van Gerven, J. M., & Drevets, W. (2019). The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. *Journal of Psychopharmacology*, *33*, 202–209. <https://doi.org/10.1177/0269881118822258> Epub 2019 Jan 15.
- Broughton, R., Valley, V., Aguirre, M., Roberts, J., Suwalski, W., & Dunham, W. (1986). Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: A laboratory perspective. *Sleep*, *9*(1 Pt 2), 205–215. <https://doi.org/10.1093/sleep/9.1.205>
- Broughton, R., Dunham, W., Newman, J., Lutley, K., Duschesne, P., & Rivers, M. (1988). Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls. *Electroencephalography and Clinical Neurophysiology*, *70*, 473–481. [https://doi.org/10.1016/0013-4694\(88\)90145-9](https://doi.org/10.1016/0013-4694(88)90145-9)
- Clark, J. W., Brian, M. L., Drummond, S. P. A., Hoyer, D., & Jacobson, L. H. (2020). Effects of orexin receptor antagonism on human sleep architecture: A systematic review. *Sleep Medicine Reviews*, *53*, 101332. <https://doi.org/10.1016/j.smrv.2020.101332> Epub 2020 May 13.
- Connor, K. M., Mahoney, E., Jackson, S., Hutzelmann, J., Zhao, X., Jia, N., Snyder, E., Snavely, D., Michelson, D., Roth, T., & Herring, W. J. (2016). A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist Filorexant (MK-6096) in patients with primary insomnia. *The International Journal of Neuropsychopharmacology*, *19*(8), pyw022. <https://doi.org/10.1093/ijnp/pyw022>
- Dauvilliers, Y., Baumann, C. R., Carlander, B., Bischof, M., Blatter, T., Lecendreux, M., Maly, F., Besset, A., Touchon, J., Billiard, M., Tafti, M., & Bassetti, C. L. (2003). CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. *Journal of Neurology, Neurosurgery & Psychiatry*, *74*, 1667–1673. <https://doi.org/10.1136/jnnp.74.12.1667>
- Dauvilliers, Y., Bauer, J., Rigau, V., Lalloyer, N., Labauge, P., Carlander, B., Liblaur, R., Peyron, C., & Lassmann, H. (2013). Hypothalamic immunopathology in anti-ma-associated diencephalitis with narcolepsy-cataplexy. *JAMA Neurology*, *70*, 1305–1310. <https://doi.org/10.1001/jamaneurol.2013.2831>
- Dauvilliers, Y., Zammit, G., Fietze, I., Mayleben, D., Seboek Kinter, D., Pain, S., & Hedner, J. (2020). Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. *Annals of Neurology*, *87*, 347–356. <https://doi.org/10.1002/ana.25680> Epub 2020 Feb 5. Erratum in: *Ann Neurol*, 88:647–651.
- De Boer, P., Drevets, W. C., Rofael, H., van der Ark, P., Kent, J. M., Kezic, I., Parapatics, S., Dorffner, G., van Gerven, J., Beneš, H., Keicher, C., Jahn, H., Seiden, D. J., & Luthringer, R. (2018). A randomized phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. *Journal of Psychopharmacology*, *32*, 668–677. <https://doi.org/10.1177/0269881118773745> Epub 2018 May 31.
- de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L., Gautvik, V. T., Bartlett, F. S., 2nd, Frankel, W. N., van den Pol, A. N., Bloom, F. E., Gautvik, K. M., & Sutcliffe, J. G. (1998). The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. *Proceedings of the National Academy of Sciences of the United States of America*, *95*, 322–327. <https://doi.org/10.1073/pnas.95.1.322>
- Deadwyler, S. A., Porrino, L., Siegel, J. M., & Hampson, R. E. (2007). Systemic and nasal delivery of orexin—A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. *Journal of Neuroscience*, *27*, 14239–14247. <https://doi.org/10.1523/JNEUROSCI.3878-07.2007>
- Dement, W., Rechtschaffen, A., & Gulevich, G. (1966). The nature of the narcoleptic sleep attack. *Neurology*, *16*, 18–33. <https://doi.org/10.1212/wnl.16.1.18>
- Dijk, D. J., Duffy, J. F., & Czeisler, C. A. (2000). Contribution of circadian physiology and sleep homeostasis to age-related changes in human sleep. *Chronobiology International*, *17*, 285–311. <https://doi.org/10.1081/cbi-100,101,049>
- Evangelista, E., Lopez, R., Barateau, L., Chenini, S., Bosco, A., Jaussent, I., & Dauvilliers, Y. (2018). Alternative diagnostic criteria for idiopathic hypersomnia: A 32-hour protocol. *Annals of Neurology*, *83*, 235–247. <https://doi.org/10.1002/ana.25141> Epub 2018 Feb 9.
- Fronczek, R., Lammers, G. J., Balesar, R., Unmehopa, U. A., & Swaab, D. F. (2005). The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. *The Journal of Clinical Endocrinology and Metabolism*, *90*, 5466–5470. <https://doi.org/10.1210/jc.2005-0296> Epub 2005 Jun 28.
- Fronczek, R., Arnulf, I., Baumann, C. R., Maski, K., Pizza, F., & Trotti, L. M. (2020). To split or to lump? Classifying the central disorders of hypersomnolence. *Sleep*, *43*, zsa044. <https://doi.org/10.1093/sleep/zsa044>
- Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E., & Nishino, S. (2003). Effects of IV and ICV hypocretin-1 (orexin a) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. *Sleep*, *26*, 953–959. <https://doi.org/10.1093/sleep/26.8.953>
- Goldbart, A., Peppard, P., Finn, L., Ruoff, C. M., Barnet, J., Young, T., & Mignot, E. (2014). Narcolepsy and predictors of positive MSLTs in the Wisconsin sleep cohort. *Sleep*, *37*, 1043–1051. <https://doi.org/10.5665/sleep.3758>
- Gotter, A. L., Forman, M. S., Harrell, C. M., Stevens, J., Svetnik, V., Yee, K. L., Li, X., Roecker, A. J., Fox, S. V., Tannenbaum, P. L.,

- Garson, S. L., Lepeleire, I. D., Calder, N., Rosen, L., Struyk, A., Coleman, P. J., Herring, W. J., Renger, J. J., & Winrow, C. J. (2016). Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man. *Scientific Reports*, 6, 27147. <https://doi.org/10.1038/srep27147>
- Grimaldi, D., Silvani, A., Benarroch, E. E., & Cortelli, P. (2014). Orexin/hypocretin system and autonomic control: New insights and clinical correlations. *Neurology*, 82, 271–278. <https://doi.org/10.1212/WNL.000000000000045> Epub 2013 Dec 20.
- Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005). A role for lateral hypothalamic orexin neurons in reward seeking. *Nature*, 437, 556–559. <https://doi.org/10.1038/nature04071> Epub 2005 Aug 14.
- Heier, M. S., Evisukova, T., Vilming, S., Gjerstad, M. D., Schrader, H., & Gautvik, K. (2007). CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. *Sleep*, 30, 969–973. <https://doi.org/10.1093/sleep/30.8.969>
- Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snively, D., Liu, K., Lines, C., Roth, T., & Michelson, D. (2012). Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant. *Neurology*, 79, 2265–2274. <https://doi.org/10.1212/WNL.0b013e31827688ee> Epub 2012 Nov 28.
- Herring, W. J., Connor, K. M., Ivgy-May, N., Snyder, E., Liu, K., Snively, D. B., Krystal, A. D., Walsh, J. K., Benca, R. M., Rosenberg, R., Sangal, R. B., Budd, K., Hutzelmann, J., Leibensperger, H., Froman, S., Lines, C., Roth, T., & Michelson, D. (2016). Suvorexant in patients with insomnia: Results from two 3-month randomized controlled clinical trials. *Biological Psychiatry*, 79, 136–148. <https://doi.org/10.1016/j.biopsych.2014.10.003> Epub 2014 Oct 23.
- Herring, W. J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., Stevens, J., Lines, C., & Michelson, D. (2020). Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: A randomized trial. *Alzheimer's & Dementia*, 16, 541–551. <https://doi.org/10.1002/alz.12035> Epub 2020 Jan 15.
- Hoever, P., Dorffner, G., Beneš, H., Penzel, T., Danker-Hopfe, H., Barbanj, M. J., Pillar, G., Saletu, B., Polo, O., Kunz, D., Zeitlhofer, J., Berg, S., Partinen, M., Bassetti, C. L., Högl, B., Ebrahim, I. O., Holsboer-Trachsler, E., Bengtsson, H., Peker, Y., ... Dingemans, J. (2012). Orexin receptor antagonism, a new sleep-enabling paradigm: A proof-of-concept clinical trial. *Clinical Pharmacology & Therapeutics*, 91, 975–985. <https://doi.org/10.1038/clpt.2011.370>
- Hunt, N. J., Rodriguez, M. L., Waters, K. A., & Machaalani, R. (2015). Changes in orexin (hypocretin) neuronal expression with normal aging in the human hypothalamus. *Neurobiology of Aging*, 36, 292–300. <https://doi.org/10.1016/j.neurobiolaging.2014.08.010> Epub 2014 Aug 13.
- Imanishi, A., Kawazoe, T., Hamada, Y., Kumagai, T., Tsutsui, K., Sakai, N., Eto, K., Noguchi, A., Shimizu, T., Takahashi, T., Han, G., Mishima, K., Kanbayashi, T., & Kondo, H. (2020). Early detection of Niemann-pick disease type C with cataplexy and orexin levels: Continuous observation with and without Miglustat. *Orphanet Journal of Rare Diseases*, 15, 269. <https://doi.org/10.1186/s13023-020-01531-4>
- Irukayama-Tomobe, Y., Ogawa, Y., Tominaga, H., Ishikawa, Y., Hosokawa, N., Ambai, S., Kawabe, Y., Uchida, S., Nakajima, R., Saitoh, T., Kanda, T., Vogt, K., Sakurai, T., Nagase, H., & Yanagisawa, M. (2017). Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. *Proceedings of the National Academy of Sciences of the United States of America*, 114, 5731–5736. <https://doi.org/10.1073/pnas.1700491114> Epub 2017 May 15.
- Ishikawa, T., Suzuki, M., Kajita, Y., Miyanoana, Y., Koike, T., & Kimura, H. (2019). Discovery of a novel, orally available orexin 2 receptor-selective agonist, TAK-994, as a therapeutic drug for narcolepsy [abstract]. *Sleep Medicine*, 64, S170.
- Ishikawa, T., Suzuki, M., Kimura, H., et al. (2020). Orally available orexin 2 receptor-selective agonist, TAK-994, shows wake-promoting effects following chronic dosing in an orexin-deficient narcolepsy mouse model [abstract no. 0141]. *Sleep*, 43(Supplement_1), A56.
- Jacobson, L. H., Hoyer, D., & de Lecea, L. (2022). Hypocretins (orexins): The ultimate translational neuropeptides. *Journal of Internal Medicine*, 291, 533–556. <https://doi.org/10.1111/joim.13406> Epub 2022 Jan 19.
- Kanbayashi, T., Yano, T., Ishiguro, H., Kawanishi, K., Chiba, S., Aizawa, R., Sawaishi, Y., Hirota, K., Nishino, S., & Shimizu, T. (2002a). Hypocretin-1 (orexin-a) levels in human lumbar CSF in different age groups: Infants to elderly persons. *Sleep*, 25, 337–339. <https://doi.org/10.1093/sleep/25.3.337>
- Kanbayashi, T., Inoue, Y., Chiba, S., Aizawa, R., Saito, Y., Tsukamoto, H., Fujii, Y., Nishino, S., & Shimizu, T. (2002b). CSF hypocretin-1 (orexin-a) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. *Journal of Sleep Research*, 11, 91–93. <https://doi.org/10.1046/j.1365-2869.2002.00284.x>
- Kanbayashi, T., Sagawa, Y., Takemura, F., Ito, S. U., Tsutsui, K., Hishikawa, Y., & Nishino, S. (2011). The pathophysiologic basis of secondary narcolepsy and hypersomnia. *Current Neurology and Neuroscience Reports*, 11, 235–241. <https://doi.org/10.1007/s11910-011-0178-y>
- Kandt, R. S., Emerson, R. G., Singer, H. S., Valle, D. L., & Moser, H. W. (1982). Cataplexy in variant forms of Niemann-pick disease. *Annals of Neurology*, 12, 284–288. <https://doi.org/10.1002/ana.410120313>
- Kantor, S., Mochizuki, T., Lops, S. N., Ko, B., Clain, E., Clark, E., Yamamoto, M., & Scammell, T. E. (2013). Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice. *Sleep*, 36, 1129–1138. <https://doi.org/10.5665/sleep.2870>
- Kärppä, M., Yardley, J., Pinner, K., Filippov, G., Zammit, G., Moline, M., Perdomo, C., Inoue, Y., Ishikawa, K., & Kubota, N. (2020). Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: Results from the phase 3 randomized clinical trial SUNRISE 2. *Sleep*, 43, zsa123. <https://doi.org/10.1093/sleep/zsaa123>
- Kaushik, M. K., Aritake, K., Imanishi, A., Kanbayashi, T., Ichikawa, T., Shimizu, T., Urade, Y., & Yanagisawa, M. (2018). Continuous intrathecal orexin delivery inhibits cataplexy in a murine model of narcolepsy. *Proceedings of the National Academy of Sciences of the United States of America*, 115, 6046–6051. <https://doi.org/10.1073/pnas.1722686115> Epub 2018 May 21.
- Kimura, H., Ishikawa, T., Yukitake, H., & Suzuki, M. (2019). An orexin 2 receptor-selective agonist, TAK-925, ameliorates narcolepsy-like symptoms and obesity in orexin/ataxin-3 transgenic mice. *Sleep*, 42, A23.
- Kornum, B. R., Knudsen, S., Ollila, H. M., Pizza, F., Jennum, P. J., Dauvilliers, Y., & Overeem, S. (2017). Narcolepsy. *Nature Reviews. Disease Primers*, 3, 16100. <https://doi.org/10.1038/nrdp.2016.100>
- Krahn, L. E., Arand, D. L., Avidan, A. Y., Davila, D. G., DeBassio, W. A., Ruoff, C. M., & Harrod, C. G. (2021). Recommended protocols for the multiple sleep latency test and maintenance of wakefulness test in adults: Guidance from the American Academy of sleep medicine. *Journal of Clinical Sleep Medicine*, 17, 2489–2498. <https://doi.org/10.5664/jcsm.9620>
- Kuwaki, T. (2015). Thermoregulation under pressure: A role for orexin neurons. *Temperature (Austin)*, 2, 379–391. <https://doi.org/10.1080/23328940.2015.1066921>
- Lammers, G. J., Bassetti, C. L. A., Dolenc-Groselj, L., Jennum, P. J., Kallweit, U., Khatami, R., Lecendreux, M., Manconi, M., Mayer, G., Partinen, M., Plazzi, G., Reading, P. J., Santamaria, J., Sonka, K., & Dauvilliers, Y. (2020). Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. *Sleep Medicine Reviews*, 52, 101306. <https://doi.org/10.1016/j.smr.2020.101306> Epub 2020 Mar 23.
- Landolfi, J. C., & Nadkarni, M. (2003). Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: Case study.

- Neuro-oncology*, 5, 214–216. <https://doi.org/10.1215/S1152851702000467>
- Lavault, S., Golmard, J. L., Groos, E., Brion, A., Dauvilliers, Y., Lecendreux, M., Franco, P., & Arnulf, I. (2015). Kleine-Levin syndrome in 120 patients: Differential diagnosis and long episodes. *Annals of Neurology*, 77, 529–540. <https://doi.org/10.1002/ana.24350> Epub 2015 Feb 4.
- Li, S. B., Damonte, V. M., Chen, C., Wang, G. X., Kebschull, J. M., Yamaguchi, H., Bian, W. J., Purmann, C., Pattni, R., Urban, A. E., Mourrain, P., Kauer, J. A., Scherrer, G., & de Lecea, L. (2022). Hyperexcitable arousal circuits drive sleep instability during aging. *Science*, 375, eabh3021. <https://doi.org/10.1126/science.abh3021> Epub 2022 Feb 25.
- Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell*, 98, 365–376. [https://doi.org/10.1016/S0092-8674\(00\)81965-0](https://doi.org/10.1016/S0092-8674(00)81965-0)
- Liu, M., Thankachan, S., Kaur, S., Begum, S., Blanco-Centurion, C., Sakurai, T., Yanagisawa, M., Neve, R., & Shiromani, P. J. (2008). Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. *The European Journal of Neuroscience*, 28, 1382–1393. <https://doi.org/10.1111/j.1460-9568.2008.06446.x>
- Liu, M., Blanco-Centurion, C., Konadhode, R., Begum, S., Pelluru, D., Gerashchenko, D., Sakurai, T., Yanagisawa, M., van den Pol, A. N., & Shiromani, P. J. (2011). Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. *Journal of Neuroscience*, 31, 6028–6040. <https://doi.org/10.1523/JNEUROSCI.6069-10.2011>
- Liu, M., Blanco-Centurion, C., Konadhode, R. R., Luan, L., & Shiromani, P. J. (2016). Orexin gene transfer into the amygdala suppresses both spontaneous and emotion-induced cataplexy in orexin-knockout mice. *The European Journal of Neuroscience*, 43, 681–688. <https://doi.org/10.1111/ejn.13158> Epub 2016 Feb 3.
- Lopez, R., Barateau, L., Chenini, S., & Dauvilliers, Y. (2015). Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine-Levin syndrome. *Sleep Medicine*, 16, 194–196. <https://doi.org/10.1016/j.sleep.2014.07.022> Epub 2014 Oct 22.
- Lopez, R., Barateau, L., Evangelista, E., Chenini, S., Robert, P., Jausent, I., & Dauvilliers, Y. (2017a). Temporal changes in the cerebrospinal fluid level of Hypocretin-1 and histamine in narcolepsy. *Sleep*, 40, zsw010. <https://doi.org/10.1093/sleep/zsw010>
- Lopez, R., Doukkali, A., Barateau, L., Evangelista, E., Chenini, S., Jausent, I., & Dauvilliers, Y. (2017b). Test–retest reliability of the multiple sleep latency test in central disorders of Hypersomnolence. *Sleep*, 40. <https://doi.org/10.1093/sleep/zsx164>
- Maresca, A., Del Dotto, V., Capristo, M., Scimonelli, E., Tagliavini, F., Morandi, L., Tropeano, C. V., Caporali, L., Mohamed, S., Roberti, M., Scandiffio, L., Zaffagnini, M., Rossi, J., Cappelletti, M., Musiani, F., Contin, M., Riva, R., Liguori, R., Pizza, F., ... Carelli, V. (2020). DNMT1 mutations leading to neurodegeneration paradoxically reflect on mitochondrial metabolism. *Human Molecular Genetics*, 29, 1864–1881. <https://doi.org/10.1093/hmg/ddaa014>
- Maski, K., Pizza, F., Liu, S., Steinhart, E., Little, E., Colclasure, A., Diniz Behn, C., Vandi, S., Antelmi, E., Weller, E., Scammell, T. E., & Plazzi, G. (2020). Defining disrupted nighttime sleep and assessing its diagnostic utility for pediatric narcolepsy type 1. *Sleep*, 43, zsa066. <https://doi.org/10.1093/sleep/zsa066>
- Maski, K., Mignot, E., Plazzi, G., & Dauvilliers, Y. (2022). Disrupted nighttime sleep and sleep instability in narcolepsy. *Journal of Clinical Sleep Medicine*, 18, 289–304. <https://doi.org/10.5664/jcsm.9638>
- Melberg, A., Hetta, J., Dahl, N., Nennesmo, I., Bengtsson, M., Wibom, R., Grant, C., Gustavson, K. H., & Lundberg, P. O. (1995). Autosomal dominant cerebellar ataxia deafness and narcolepsy. *Journal of Neurological Sciences*, 134, 119–129. [https://doi.org/10.1016/0022-510x\(95\)00228-0](https://doi.org/10.1016/0022-510x(95)00228-0)
- Melberg, A., Ripley, B., Lin, L., Hetta, J., Mignot, E., & Nishino, S. (2001). Hypocretin deficiency in familial symptomatic narcolepsy. *Annals of Neurology*, 49, 136–137.
- Michelson, D., Snyder, E., Paradis, E., Chengan-Liu, M., Snively, D. B., Hutzelmann, J., Walsh, J. K., Krystal, A. D., Benca, R. M., Cohn, M., Lines, C., Roth, T., & Herring, W. J. (2014). Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. *The Lancet. Neurology*, 13, 461–471. [https://doi.org/10.1016/S1474-4422\(14\)70053-5](https://doi.org/10.1016/S1474-4422(14)70053-5) Epub 2014 Mar 27.
- Mieda, M., Willie, J. T., Hara, J., Sinton, C. M., Sakurai, T., & Yanagisawa, M. (2004). Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. *Proceedings of the National Academy of Sciences of the United States of America*, 101, 4649–4654. <https://doi.org/10.1073/pnas.0400590101> Epub 2004 Mar 16.
- Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Vankova, J., Black, J., Harsh, J., Bassetti, C., Schrader, H., & Nishino, S. (2002). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Archives of Neurology*, 59, 1553–1562. <https://doi.org/10.1001/archneur.59.10.1553>
- Mignot, E., Mayleben, D., Fietze, I., Leger, D., Zammit, G., Bassetti, C. L. A., Pain, S., Kinter, D. S., Roth, T., & investigators. (2022). Safety and efficacy of daridorexant in patients with insomnia disorder: Results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. *The Lancet. Neurology*, 21, 125–139. [https://doi.org/10.1016/S1474-4422\(21\)00436-1](https://doi.org/10.1016/S1474-4422(21)00436-1) Erratum in: *Lancet Neurol*. 2022 Jan 20; Erratum in: *Lancet Neurol*. 2022 Apr 5.
- Moghadam, K. K., Pizza, F., La Morgia, C., Franceschini, C., Tonon, C., Lodi, R., Barboni, P., Seri, M., Ferrari, S., Liguori, R., Donadio, V., Parchi, P., Cornelio, F., Inzitari, D., Mignarri, A., Capocchi, G., Dotti, M. T., Winkelmann, J., Lin, L., ... Plazzi, G. (2014). Narcolepsy is a common phenotype in HSN IE and ADCA-DN. *Brain*, 137, 1643–1655. <https://doi.org/10.1093/brain/awu069> Epub 2014 Apr 10.
- Murphy, P., Moline, M., Mayleben, D., Rosenberg, R., Zammit, G., Pinner, K., Dhadda, S., Hong, Q., Giorgi, L., & Satlin, A. (2017). Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: Results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study. *Journal of Clinical Sleep Medicine*, 13, 1289–1299. <https://doi.org/10.5664/jcsm.6800>
- Nishino, S., Ripley, B., Overeem, S., Lammers, G. J., & Mignot, E. (2000). Hypocretin (orexin) deficiency in human narcolepsy. *Lancet*, 355(9197), 39–40. [https://doi.org/10.1016/S0140-6736\(99\)05582-8](https://doi.org/10.1016/S0140-6736(99)05582-8)
- Nishino, S., & Kanbayashi, T. (2005). Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. *Sleep Medicine Reviews*, 9, 269–310. <https://doi.org/10.1016/j.smrv.2005.03.004>
- Ohayon, M. M., Carskadon, M. A., Guilleminault, C., & Vitiello, M. V. (2004). Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: Developing normative sleep values across the human lifespan. *Sleep*, 27, 1255–1273. <https://doi.org/10.1093/sleep/27.7.1255>
- Overeem, S., Dalmau, J., Bataller, L., Nishino, S., Mignot, E., Verschuuren, J., & Lammers, G. J. (2004). Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. *Neurology*, 62, 138–140. <https://doi.org/10.1212/01.wnl.0000101718.92619.67>
- Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. *Journal of Neuroscience*, 18, 9996–10015. <https://doi.org/10.1523/JNEUROSCI.18-23-09996.1998>
- Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y., Nevsimalova, S., Aldrich, M., Reynolds, D., Albin, R., Li, R., Hungs, M., Pedrazzoli, M., Padigaru, M., Kucherlapati, M., Fan, J., Maki, R., Lammers, G. J., Bouras, C., ... Mignot, E. (2000). A mutation in a case of

- early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nature Medicine*, 6, 991–997. <https://doi.org/10.1038/79690>
- Pillen, S., Pizza, F., Dhondt, K., Scammell, T. E., & Overeem, S. (2017). Catalepsy and its mimics: Clinical recognition and management. *Current Treatment Options in Neurology*, 19, 23. <https://doi.org/10.1007/s11940-017-0459-0>
- Pizza, F., Vandi, S., Liguori, R., Parchi, P., Avoni, P., Mignot, E., & Plazzi, G. (2014). Primary progressive narcolepsy type 1: The other side of the coin. *Neurology*, 83, 2189–2190. <https://doi.org/10.1212/WNL.0000000000001051> Epub 2014 Oct 29.
- Pizza, F., Vandi, S., Ilti, M., Franceschini, C., Liguori, R., Mignot, E., & Plazzi, G. (2015). Nocturnal sleep dynamics identify narcolepsy type 1. *Sleep*, 38, 1277–1284. <https://doi.org/10.5665/sleep.4908>
- Podestà, C., Ferreras, M., Mozzi, M., Bassetti, C., Dauvilliers, Y., & Billiard, M. (2006). Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements. *Sleep Medicine*, 7, 649–651. <https://doi.org/10.1016/j.sleep.2006.07.003> Epub 2006 Nov 13.
- Postiglione, E., Barateau, L., Pizza, F., Lopez, R., Antelmi, E., Rassu, A. L., Vandi, S., Chenini, S., Mignot, E., Dauvilliers, Y., & Plazzi, G. (2022). Narcolepsy with intermediate cerebrospinal level of hypocretin-1. *Sleep*, 45, zsab285. <https://doi.org/10.1093/sleep/zsab285>
- Ripley, B., Overeem, S., Fujiki, N., Nevsimalova, S., Uchino, M., Yesavage, J., Di Monte, D., Dohi, K., Melberg, A., Lammers, G. J., Nishida, Y., Roelandse, F. W., Hungs, M., Mignot, E., & Nishino, S. (2001). CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. *Neurology*, 57, 2253–2258. <https://doi.org/10.1212/wnl.57.12.2253>
- Rosenberg, R., Murphy, P., Zammit, G., Mayleben, D., Kumar, D., Dhadda, S., Filippov, G., LoPresti, A., & Moline, M. (2019). Comparison of Lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: A phase 3 randomized clinical trial. *JAMA Network Open*, 2, e1918254. <https://doi.org/10.1001/jamanetworkopen.2019.18254> Erratum in: *JAMA Netw Open*. 2020 Apr 1;3(4):e206497. Erratum in: *JAMA Netw Open*. 2021 Aug 2;4(8):e2127643.
- Rossi, S., Asioli, G. M., Rizzo, G., Sallemi, G., Moresco, M., Franceschini, C., Pizza, F., & Plazzi, G. (2021). Onset of narcolepsy type 1 in a paraneoplastic encephalitis associated with a thymic seminoma. *Journal of Clinical Sleep Medicine*, 17, 2557–2560. <https://doi.org/10.5664/jcsm.9496>
- Roth, B. (1981). Idiopathic hypersomnia: A study of 187 personally observed cases. *International Journal of Neurology*, 15, 108–118.
- Roth, T., Black, J., Cluydts, R., Charef, P., Cavallaro, M., Kramer, F., Zammit, G., & Walsh, J. (2017). Dual orexin receptor antagonist, almorexant, in elderly patients with primary insomnia: A randomized, controlled study. *Sleep*, 40. <https://doi.org/10.1093/sleep/zsw034>
- Ruoff, C., Pizza, F., Trotti, L. M., Sonka, K., Vandi, S., Cheung, J., Pinto, S., Einen, M., Simakajornboon, N., Han, F., Peppard, P., Nevsimalova, S., Plazzi, G., Rye, D., & Mignot, E. (2018). The MSLT is repeatable in narcolepsy type 1 but not narcolepsy type 2: A retrospective patient study. *Journal of Clinical Sleep Medicine*, 14, 65–74. <https://doi.org/10.5664/jcsm.6882>
- Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., ... Yanagisawa, M. (1998). Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell*, 92, 573–585. [https://doi.org/10.1016/s0092-8674\(00\)80949-6](https://doi.org/10.1016/s0092-8674(00)80949-6)
- Sakurai, T., & Mieda, M. (2011). Connectomics of orexin-producing neurons: Interface of systems of emotion, energy homeostasis and arousal. *Trends in Pharmacological Sciences*, 32, 451–462. <https://doi.org/10.1016/j.tips.2011.03.007> Epub 2011 May 11.
- Sakurai, T. (2014). The role of orexin in motivated behaviours. *Nature Reviews Neuroscience*, 15, 719–731. <https://doi.org/10.1038/nrn3837> Epub 2014 Oct 10.
- Saper, C. B., Scammell, T. E., & Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. *Nature*, 437(7063), 1257–1263. <https://doi.org/10.1038/nature04284>
- Suzuki, M., Yukitake, H., Ishikawa, T., & Kimura, H. (2018). 0001 an orexin 2 receptor-selective agonist TAK-925 ameliorates narcolepsy-like symptoms in orexin/ ataxin-3 mice. *Sleep*, 41, A1.
- Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M., & Siegel, J. M. (2000). Reduced number of hypocretin neurons in human narcolepsy. *Neuron*, 27, 469–474. [https://doi.org/10.1016/s0896-6273\(00\)00058-1](https://doi.org/10.1016/s0896-6273(00)00058-1)
- Thannickal, T. C., Nienhuis, R., & Siegel, J. M. (2009). Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. *Sleep*, 32, 993–998. <https://doi.org/10.1093/sleep/32.8.993>
- Trotti, L. M., Staab, B. A., & Rye, D. B. (2013). Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. *Journal of Clinical Sleep Medicine*, 9, 789–795. <https://doi.org/10.5664/jcsm.2922>
- Usuda, M., Kodaira, M., Ogawa, Y., Kanbayashi, T., Yanagisawa, S., & Sekijima, Y. (2018). Fluctuating CSF hypocretin-1 levels in mild brain trauma-induced Kleine-Levin syndrome. *Journal of Neurological Sciences*, 391, 10–11. <https://doi.org/10.1016/j.jns.2018.05.011> Epub 2018 May 17.
- van der Hoeven, A. E., Fronczek, R., Schinkelshoek, M. S., Roelandse, F. W. C., Bakker, J. A., Overeem, S., Bijlenga, D., & Lammers, G. J. (2022). Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: Their significance in the diagnosis of narcolepsy type 1. *Sleep*, 45, zsa052. <https://doi.org/10.1093/sleep/zsa052> Epub ahead of print.
- Vernet, C., & Arnulf, I. (2009). Idiopathic hypersomnia with and without long sleep time: A controlled series of 75 patients. *Sleep*, 32, 753–759. <https://doi.org/10.1093/sleep/32.6.753>
- Vitiello, M., Antelmi, E., Pizza, F., Postiglione, E., Poggi, R., Liguori, R., & Plazzi, G. (2018). Type 1 narcolepsy in anti-Hu antibodies mediated encephalitis: A case report. *Sleep Medicine*, 52, 23–25. <https://doi.org/10.1016/j.sleep.2018.02.003> Epub 2018 Feb 21.
- Wang, J. Y., Han, F., Dong, S. X., Li, J., An, P., Zhang, X. Z., Chang, Y., Zhao, L., Zhang, X. L., Liu, Y. N., Yan, H., Li, Q. H., Hu, Y., Lv, C. J., Gao, Z. C., & Strohl, K. P. (2016). Cerebrospinal fluid orexin a levels and autonomic function in Kleine-Levin syndrome. *Sleep*, 39, 855–860. <https://doi.org/10.5665/sleep.5642>
- Weinhold, S. L., Seeck-Hirschner, M., Nowak, A., Hallschmid, M., Göder, R., & Baier, P. C. (2014). The effect of intranasal orexin-a (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. *Behavioural Brain Research*, 262, 8–13. <https://doi.org/10.1016/j.bbr.2013.12.045> Epub 2014 Jan 7.
- Winkelmann, J., Lin, L., Schormair, B., Kornum, B. R., Faraco, J., Plazzi, G., Melberg, A., Cornelio, F., Urban, A. E., Pizza, F., Poli, F., Grubert, F., Wieland, T., Graf, E., Hallmayer, J., Strom, T. M., & Mignot, E. (2012). Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. *Human Molecular Genetics*, 21, 2205–2210. <https://doi.org/10.1093/hmg/dds035> Epub 2012 Feb 9.
- Xue, T., Wu, X., Chen, S., Yang, Y., Yan, Z., Song, Z., Zhang, W., Zhang, J., Chen, Z., & Wang, Z. (2022). The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. *Sleep Medicine Reviews*, 61, 101573. <https://doi.org/10.1016/j.smrv.2021.101573> Epub 2021 Nov 26.
- Yamanaka, A., Sakurai, T., Katsumoto, T., Yanagisawa, M., & Goto, K. (1999). Chronic intracerebroventricular administration of orexin-a to rats increases food intake in daytime, but has no effect on body weight. *Brain Research*, 849, 248–252. [https://doi.org/10.1016/s0006-8993\(99\)01905-8](https://doi.org/10.1016/s0006-8993(99)01905-8)
- Yukitake, H., Fujimoto, T., Ishikawa, T., Suzuki, A., Shimizu, Y., Rikimaru, K., Ito, M., Suzuki, M., & Kimura, H. (2019). TAK-925, an orexin

2 receptor-selective agonist, shows robust wake-promoting effects in mice. *Pharmacology, Biochemistry, and Behavior*, 187, 172794. <https://doi.org/10.1016/j.pbb.2019.172794> Epub 2019 Oct 22.

Zammit, G., Dauvilliers, Y., Pain, S., Sebök Kinter, D., Mansour, Y., & Kunz, D. (2020). Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. *Neurology*, 94, e2222–e2232. <https://doi.org/10.1212/WNL.0000000000009475> Epub 2020 Apr 27.